share_log

CVS Health | 8-K: Current report

CVS Health | 8-K: Current report

西维斯健康 | 8-K：重大事件
美股sec公告 ·  05/22 16:35
Moomoo AI 已提取核心信息
On May 16, 2024, CVS Health Corporation conducted its 2024 Annual Meeting of Stockholders, where several key proposals were voted upon. The stockholders approved an amendment to the 2017 Incentive Compensation Plan (2017 ICP), which will increase the number of common shares available for issuance by 33.5 million. This amendment had previously received approval from the Management Planning and Development Committee and the Board of Directors, contingent on stockholder approval. The meeting also resulted in the election of 12 nominees to the Board of Directors for a one-year term, the ratification of Ernst & Young LLP as the independent registered public accounting firm for 2024, and the advisory approval of the compensation of the company's named executive officers. However, four stockholder proposals were not approved. The detailed voting results for each proposal were provided in the report. The amended 2017 ICP and the forms of award agreements to be used under the plan were filed as exhibits to the report.
On May 16, 2024, CVS Health Corporation conducted its 2024 Annual Meeting of Stockholders, where several key proposals were voted upon. The stockholders approved an amendment to the 2017 Incentive Compensation Plan (2017 ICP), which will increase the number of common shares available for issuance by 33.5 million. This amendment had previously received approval from the Management Planning and Development Committee and the Board of Directors, contingent on stockholder approval. The meeting also resulted in the election of 12 nominees to the Board of Directors for a one-year term, the ratification of Ernst & Young LLP as the independent registered public accounting firm for 2024, and the advisory approval of the compensation of the company's named executive officers. However, four stockholder proposals were not approved. The detailed voting results for each proposal were provided in the report. The amended 2017 ICP and the forms of award agreements to be used under the plan were filed as exhibits to the report.
2024年5月16日，CVS Health Corporation举行了2024年年度股东大会，会上对几项关键提案进行了表决。股东批准了2017年激励薪酬计划（2017年ICP）的修正案，该修正案将使可供发行的普通股数量增加3,350万股。该修正案此前已获得管理规划与发展委员会和董事会的批准，但须经股东批准。会议还选举了12名董事会候选人，任期一年，安永会计师事务所批准为2024年的独立注册会计师事务所，并咨询性地批准了公司指定执行官的薪酬。但是，有四份股东提案未获批准。报告中提供了每项提案的详细投票结果。经修订的2017年ICP和计划中使用的奖励协议形式已作为报告的证物提交。
2024年5月16日，CVS Health Corporation举行了2024年年度股东大会，会上对几项关键提案进行了表决。股东批准了2017年激励薪酬计划（2017年ICP）的修正案，该修正案将使可供发行的普通股数量增加3,350万股。该修正案此前已获得管理规划与发展委员会和董事会的批准，但须经股东批准。会议还选举了12名董事会候选人，任期一年，安永会计师事务所批准为2024年的独立注册会计师事务所，并咨询性地批准了公司指定执行官的薪酬。但是，有四份股东提案未获批准。报告中提供了每项提案的详细投票结果。经修订的2017年ICP和计划中使用的奖励协议形式已作为报告的证物提交。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息